Degarelix Powder and Solvent for Suspension for Injection.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 12 May 2009 Additional locations (Romania, Hungary, Czech Republic) identified as reported by ClinicalTrials.gov.
- 12 May 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 12 May 2009 Patient number changed from 127 to 133 as reported by ClinicalTrials.gov.